The estimated Net Worth of Christina Ackermann is at least $5.24 Millón dollars as of 26 February 2022. Ms. Ackermann owns over 24,292 units of Bausch Health Companies Inc stock worth over $1,186,891 and over the last 8 years she sold BHC stock worth over $673,431. In addition, she makes $3,379,930 as Executive Vice President y General Counsel at Bausch Health Companies Inc.
Sign up
Ms. Ackermann BHC stock SEC Form 4 insiders trading
Christina has made over 8 trades of the Bausch Health Companies Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 24,292 units of BHC stock worth $154,983 on 26 February 2022.
The largest trade she's ever made was exercising 121,198 units of Bausch Health Companies Inc stock on 2 June 2021 worth over $1,799,790. On average, Christina trades about 5,529 units every 35 days since 2016. As of 26 February 2022 she still owns at least 186,033 units of Bausch Health Companies Inc stock.
You can see the complete history of Ms. Ackermann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christina Ackermann biography
Christina Ackermann is Executive Vice President, General Counsel of the Company. Prior to joining Bausch Health, Ms. Ackermann was part of the Novartis group of companies for the 14 years, most recently serving as Senior Vice President, General Counsel for Alcon, where she was responsible for the Legal, Intellectual Property and Compliance functions. She previously served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers & acquisitions.
What is the salary of Christina Ackermann?
As the Executive Vice President y General Counsel of Bausch Health Companies Inc, the total compensation of Christina Ackermann at Bausch Health Companies Inc is $3,379,930. There are 5 executives at Bausch Health Companies Inc getting paid more, with Joseph Papa having the highest compensation of $17,141,600.
How old is Christina Ackermann?
Christina Ackermann is 55, she's been the Executive Vice President y General Counsel of Bausch Health Companies Inc since 2016. There are 17 older and 5 younger executives at Bausch Health Companies Inc. The oldest executive at Bausch Health Companies Inc is Richard De Schutter, 79, who is the Independent Director.
What's Christina Ackermann's mailing address?
Christina's mailing address filed with the SEC is 3 MORE LONDON RIVERSIDE, , LONDON, X0, SE1 2RE.
Insiders trading at Bausch Health Companies Inc
Over the last 6 years, insiders at Bausch Health Companies Inc have traded over $2,786,244 worth of Bausch Health Companies Inc stock and bought 6,317,686 units worth $110,094,785 . The most active insiders traders include John Paulson, Argeris N Karabelas y Brett Icahn. On average, Bausch Health Companies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $824,564. The most recent stock trade was executed by Seana Carson on 5 September 2024, trading 13,370 units of BHC stock currently worth $83,028.
What does Bausch Health Companies Inc do?
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
What does Bausch Health Companies Inc's logo look like?
Complete history of Ms. Ackermann stock trades at Verona Pharma Plc, Bausch Health Companies Inc y Graybug Vision
Bausch Health Companies Inc executives and stock owners
Bausch Health Companies Inc executives and other stock owners filed with the SEC include:
-
Joseph Papa,
Chairman of the Board, Chief Executive Officer -
Paul Herendeen,
Chief Financial Officer, Executive Vice President -
Joseph C. Papa,
CEO & Chairman -
Thomas Appio,
President & Co-Head Bausch + Lomb/International -
William Humphries,
-
Christina Ackermann,
Executive Vice President, General Counsel -
Thomas J. Appio,
Pres & Co-Head Bausch + Lomb/International -
Paul S. Herendeen,
Exec. VP and Advisor to Chairman & CEO -
Joseph Gordon,
President & Co-Head Bausch + Lomb/International -
Christina M. Ackermann,
Exec. VP, Gen. Counsel & Head of Commercial Operations -
Thomas Ross,
Lead Independent Director -
Russel Robertson,
Independent Director -
Robert Power,
Independent Director -
Argeris Karabelas,
Independent Director -
Sarah Kavanagh,
Independent Director -
D. Robert Hale,
Independent Director -
Amy Wechsler,
Independent Director -
Richard De Schutter,
Independent Director -
Andrew Charles von Eschenbach,
Independent Director -
John Paulson,
Independent Director -
Tom G. Vadaketh,
Chief Financial Officer -
Frederick J. Munsch,
Controller & Chief Accounting Officer -
Kelly Webber,
Sr. VP & Chief HR Officer -
Stacey Williams,
VP of Marketing -
Michael McMyne,
VP of Sales -
Arthur J. Shannon,
Sr. VP and Head of Investor Relations & Communications -
Dr. Robert F. Butz,
VP of Medical & Scientific Affairs -
Osama A. Eldessouky,
CFO & Exec. VP -
Christian A Garcia,
Director -
Frank D. Lee,
Director -
Mark C. Mc Kenna,
President, Salix -
Holdings, L.P.Value Act Hol...,
-
Brett Icahn,
Director -
Steven D Miller,
Director -
Tom George Vadaketh,
EVP, Chief Financial Officer -
Holdings, L.P.Value Act Cap...,
-
Aimee J. Lenar,
EVP, US Pharma -
Seana Carson,
EVP, General Counsel -
David Robert Value Act Hold...,
-
Sam Eldessouky,
EVP & Chief Financial Officer -
Frederick Munsch,
SVP, Controller and CAO -
Robert Spurr,
President, U.S. Businesses -
Richard Mulligan,
Director -
John S Barresi,
SVP, Controller & CAO -
Jean Jacques Charhon,
EVP, CFO